News & Updates

Individuals with a persistently high or an increasing pattern of general and central obesity trajectories throughout middle and late life appear to be at greater risk of cognitive decline and developing dementia, a study has shown.

Initial findings from the ongoing VIVID-2 open-label extension (OLE) study comprising week 52 endoscopic responders from the phase III VIVID-1 trial demonstrate the long-term clinical and endoscopic efficacy of the selective anti-interleukin-23p19 monoclonal antibody mirikizumab for the treatment of moderate-to-severe active Crohn’s disease (CD).